Company intelligence / Profile preview

Sponsor No. 051072

Dublin, Ireland

Ownership: Private
Employees: ~2000
Development stage: Other

Overview

Horizon Therapeutics is a global biotechnology company focused on discovering, developing, and commercializing medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company is best known for its leadership in the treatment of thyroid eye disease with Tepezza and chronic refractory gout with Krystexxa. Horizon maintains a robust pipeline of biologics and small molecules targeting various immunological pathways. In October 2023, the company was acquired by Amgen, significantly expanding Amgen's rare disease portfolio and global reach.

Therapeutic areas: EndocrinologyRheumatologyNeurologyMetabolic Disorders
Modalities: Monoclonal antibodySmall moleculeProteinBiologic
Industry: Biotech

Partnerships

Arrowhead PharmaceuticalsHemoShear TherapeuticsAlpine Immune Sciences

Beyond the preview

Go deeper on Sponsor No. 051072.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sponsor No. 051072.

Explore the full profile